Print this page    •   Back to Web version of article

News Briefs
U.S. Approves New Once-a-Day AIDS Drug From Glaxo Rival

July 3, 2003

Gilead Sciences received approval from the US Food and Drug Administration Wednesday for a new once-a-day AIDS drug, Emtriva. Known generically as emtricitabine, Emtriva is a nucleoside reverse transcriptase inhibitor. Gilead now hopes to combine Emtriva with its other HIV drug, Viread, which is also taken once a day. The company is planning a clinical trial to test such a combination pill against Combivir, rival drug maker Glaxo's once-a-day pill combining lamivudine and AZT. But even as two separate pills, said Gilead CFO John Milligan, Viread and Emtriva could compete immediately against Combivir. Gilead said the wholesale price of Emtriva would be about $250 a month.

Back to other CDC news for July 3, 2003

Previous Updates

Excerpted from:
New York Times
07.03.03; Andrew Pollack




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art28660.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.